Vita 34 AG is a leading biotech company that specializes in stem cell banking. The company's corporate philosophy is based on three core values: responsibility, innovation, and quality. Vita 34 AG is committed to taking responsibility for the long-term health preservation of individuals and their families by offering secure and reliable stem cell storage solutions. Through constant innovation, the company strives to stay at the forefront of stem cell technologies, ensuring the highest standards of quality and safety. Vita 34 AG believes in the immense potential of stem cells and their ability to revolutionize medical treatments, making them a trusted and forward-thinking partner in the field of regenerative medicine.

Vita 34 AG is primarily present in Germany, Austria, Switzerland, and other European countries.

Vita 34 AG has achieved significant milestones in its history. It is noteworthy that the company pioneered the storage of umbilical cord blood as regenerative medicine in Europe. With over 20 years of experience, Vita 34 has established itself as a leading provider of stem cell banking services, offering secure and reliable storage options for families. The company has successfully expanded its operation to various countries, including Austria, Switzerland, and Brazil. Vita 34 AG continues to invest in research and development, ensuring cutting-edge technologies and future advancements in the field of stem cell preservation.

Vita 34 AG is a German company that specializes in the field of stem cell banking. Established in 1997, Vita 34 is one of the oldest and largest stem cell banks in Europe. The company provides individuals the opportunity to store stem cells from umbilical cord blood and tissue which can be used in potential future medical treatments. Vita 34 AG's vision has always been to contribute to the development of innovative medical therapies and improve the quality of life for patients. With a strong focus on research and technological advancements, Vita 34 AG continues to be a leading player in the stem cell industry.

The main competitors of Vita 34 AG in the market include Cryo-Save AG, Cryo-Vita GmbH, StemCyte Inc., LifeCell International Pvt. Ltd, and Cordlife Group Limited.

Vita 34 AG is primarily active in the biotechnology and healthcare industries.

Vita 34 AG's business model focuses on stem cell banking and regenerative medicine. As a biotechnology company, Vita 34 AG specializes in the collection, processing, and storage of stem cells derived from umbilical cord blood. By offering parents the opportunity to preserve their newborn's cord blood, Vita 34 AG contributes to potential future medical treatments and therapies. Through extensive quality control and state-of-the-art technologies, Vita 34 AG ensures the safe and professional handling of stem cells. With a strong emphasis on research and development, Vita 34 AG continues to advance its expertise in regenerative medicine, aiming to harness the potential of stem cells for various health-related applications.

Vita 34 KGV ir -44,57.

Vita 34 KUV ir 0,78.

AlleAktien kvalitātes vērtējums Vita 34 ir 3/10.

gaidāmā Vita 34 apgrozījums ir 81,81 milj. EUR.

gaidāmā Vita 34 peļņa ir -1,43 milj. EUR.

The Vita 34 AG is a leading company in the field of stem cell storage for medical purposes. The company's business model includes various divisions to provide its customers with tailored solutions for stem cell storage. The main division of Vita 34 is the storage of stem cells for newborns. In this case, the company extracts valuable stem cells from the umbilical cord of the newborn during umbilical cord blood donation and stores them properly in a specially developed cryogenic storage system. These stem cells can be used later for the treatment of life-threatening diseases. Vita 34 also offers a storage solution for adults. With peripheral stem cell storage, stem cells can be taken from an adult's blood and stored. These stem cells can be effectively used for the treatment of diseases such as cancer and autoimmune diseases. Another division of the company is the sale of stem cell products. Vita 34 offers various products derived from the body's own stem cell material. This includes, among other things, the VitaPlus umbilical cord blood serum as a cosmetic product for skincare and the VitaMine&More dietary supplement. Both products contain important components from stem cells that support the body's immune system and promote well-being. In addition, Vita 34 offers a comprehensive service platform that supports customers with all questions related to stem cell therapy. This includes, among other things, consultations with medical experts and support in finding suitable therapy centers and methods. The business model of Vita 34 AG is strongly focused on customer orientation. The company offers its customers tailored solutions for stem cell storage as well as comprehensive consulting and service. This makes the company a worldwide leading provider of stem cell-based solutions for medical purposes.

Vita 34 izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Vita 34 vai uzņēmums nedod dividendes.

Vita 34 ISIN ir DE000A0BL849.

Vita 34 WKN ir A0BL84.

Vita 34 simbols ir V3V.DE.

Pēdējo 12 mēnešu laikā Vita 34 maksāja dividendes 0,16 EUR apmērā. Tas atbilst aptuveni 4,00 % dividendes ražībai. Nākamajos 12 mēnešos Vita 34 plāno maksāt dividendes -0,02 EUR apmērā.

Vita 34 pašreizējā dividendu rentabilitāte ir 4,00 %.

Vita 34 maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos septembris, jūlijs, jūnijs, jūlijs.

Vita 34 pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā -0,02 EUR. Tas atbilst dividendes ražībai -0,41 %.

Vita 34 tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Vita 34 apmērā 0,16 EUR, kas tika izmaksāta 7.06.2019., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.06.2019..

Pēdējās dividendes izmaksa notika 7.06.2019..

Gadā 2023, Vita 34 izmaksāja 0 EUR dividendes.

Vita 34 dividendes tiek izmaksātas EUR.